Agilent Technologies will introduce its Sureselect Human All Exon Kit at the Cambridge Health Institute's Next-Generation Sequencing Analysis conference.
The company said the kit extends the efficiency and cost-effectiveness of the Sureselect target-enrichment system to studies of all human exons, a region totalling approximately 38Mb.
The kit is offered in sizes appropriate for studies comprised of a few to several thousand samples.
The in-solution-based Sureselect target-enrichment system scales up and is well-suited for automation, according to Agilent.
The Sureselect Human All Exon kit design covers 1.22 per cent of human genomic regions corresponding to the NCBI Consensus CDS Database, including more than 700 human miRNAs from the Sanger v13 database and more than 300 additional human non-coding RNAs in a single tube.
Sureselect Human All Exon kits will be available for both the Illumina GA II and Life Technologies' Solid system, with the initial product offered for paired-end sequencing on the system from Illumina.
The product optimised for Solid will follow shortly.
Agilent's Sureselect target-enrichment system is a platform with optimised protocols for a diverse set of sequencing protocols and platforms.
It supports Illumina end-sequencing and paired-end sequencing protocols in addition to fragment library format sequencing on the Solid system.
This technology enables users of Agilent's eArray on-line design tool to improve the efficiency of their research by allowing them to design custom products to target 5-6 Mb of any genome of interest in a single tube.
